Breaking News, Collaborations & Alliances

Kangstem Selects MaSTherCell as CDMO Partner

MaSTherCell will perform a technology transfer of FURESTEM-AD’s process & manufacture for Kangstem’s European clinical trial

Kangstem Biotech announces the selection of MaSTherCell as its contract manufacturing partner for its European clinical trial of FURESTEM-AD(R).    MaSTherCell, a subsidiary of Orgenesis Inc., is a cell therapy dedicated Contract Development and Manufacturing Organization. MaSTherCell will perform a technology transfer of FURESTEM-AD’s process and manufacture FURESTEM-AD for Kangstem’s European clinical trial. “The European clinical trial of Furestem-AD will be a milestone for our c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters